Unknown

Dataset Information

0

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.


ABSTRACT: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

SUBMITTER: Friend R 

PROVIDER: S-EPMC5367738 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): NCT02272803

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5026292 | BioStudies
1000-01-01 | S-EPMC6230619 | BioStudies
2017-01-01 | S-EPMC5513822 | BioStudies
1000-01-01 | S-EPMC5599094 | BioStudies
2015-01-01 | S-EPMC4282702 | BioStudies
2018-01-01 | S-EPMC5841936 | BioStudies
2016-01-01 | S-EPMC4959642 | BioStudies
2014-01-01 | S-EPMC4438995 | BioStudies
2018-01-01 | S-EPMC6205184 | BioStudies
1000-01-01 | S-EPMC5728054 | BioStudies